Filing Flows › GeneDx Holdings (WGS) › Q3 2026 › vs Q3 2025
GeneDx Holdings (WGS) Q3 2026 vs Q3 2025 (year over year)
GeneDx Holdings's revenue rose $6.4M (+5%) from $117M in Q3 2025 to $123M in Q3 2026. The biggest changes: Diagnostic Test +$7.1M (+6%); Other revenue −$178K (-6%).
GeneDx Holdings, Q3 2026: revenue $123M (+5% year over year), operating margin -8.5%, net loss $12.3M, operating cash flow −$10.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Patients with third-party insurance | $104M | $95.0M | $8.9M | +9% |
| Institutional customers | $16.1M | $17.9M | −$1.8M | -10% |
| Diagnostic Test | $120M | $113M | $7.1M | +6% |
| Other revenue | $3.0M | $3.2M | −$178K | -6% |
| Revenue | $123M | $117M | $6.4M | +5% |
| Net loss | $12.3M | $7.6M | $4.7M | +61% |
| Costs & expenses | $135M | $124M | $11.1M | +9% |
| Operating costs | $134M | $120M | $13.5M | +11% |
| Interest & other, net | $1.9M | $4.1M | −$2.3M | -55% |
| Income tax | $26K | $247K | −$221K | -89% |
| Cost of revenue | $37.0M | $32.2M | $4.8M | +15% |
| Research & development | $17.4M | $19.8M | −$2.5M | -12% |
| Operating cash sources | $25.7M | $1.3M | $24.5M | 20× |
| Depreciation & amortization | $6.9M | $6.5M | $421K | +7% |
| Share-based compensation | $8.3M | $10.6M | −$2.3M | -22% |
| Cash used in operations | $10.6M | −$15.8M | $26.4M | — |
| Net loss absorbed | $12.3M | $7.6M | $4.7M | +61% |
| Working capital & other | $13.4M | −$6.3M | $19.8M | — |
Questions
How much did GeneDx Holdings's revenue grow year over year in Q3 2026?
GeneDx Holdings's revenue rose $6.4M (+5%) from $117M in Q3 2025 to $123M in Q3 2026.
What drove GeneDx Holdings's revenue change in Q3 2026?
Diagnostic Test +$7.1M (+6%); Other revenue −$178K (-6%).